Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen vectibix (panitumumab — Metastatic Colorectal Cancer) — U.S. product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

Quarterly Annual

Latest, Q2 2026

167

Period ended Jun 30, 2026

Change on a year earlier

+16.0%

144 in Q2 2025

History

32 quarters

Since Q3 2018

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Vectibix (panitumumab — Metastatic Colorectal Cancer) — U.S. product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	167	+16.0%	Form 10-Q (filed 2026-08-05) ↗
Q1 2026	Mar 31, 2026	136	+0.7%	Form 10-Q (filed 2026-05-01) ↗
Q4 2025	Dec 31, 2025	163	+21.6%	Form 10-K (filed 2026-02-13) ↗
Q3 2025	Sep 30, 2025	162	+22.7%	Form 10-Q (filed 2025-11-05) ↗
Q2 2025	Jun 30, 2025	144	+8.3%	Form 10-Q (filed 2026-08-05) ↗
Q1 2025	Mar 31, 2025	135	+12.5%	Form 10-Q (filed 2026-05-01) ↗
Q4 2024	Dec 31, 2024	134	+15.5%	Form 10-K (filed 2026-02-13) ↗
Q3 2024	Sep 30, 2024	132	+13.8%	Form 10-Q (filed 2025-11-05) ↗
Q2 2024	Jun 30, 2024	133	+12.7%	Form 10-Q (filed 2025-08-06) ↗
Q1 2024	Mar 31, 2024	120	+8.1%	Form 10-Q (filed 2025-05-02) ↗
Q4 2023	Dec 31, 2023	116	+6.4%	Form 10-K (filed 2026-02-13) ↗
Q3 2023	Sep 30, 2023	116	+9.4%	Form 10-Q (filed 2024-10-31) ↗
Q2 2023	Jun 30, 2023	118	+22.9%	Form 10-Q (filed 2024-08-07) ↗
Q1 2023	Mar 31, 2023	111	+30.6%	Form 10-Q (filed 2024-05-03) ↗
Q4 2022	Dec 31, 2022	109	+18.5%	Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022	Sep 30, 2022	106	+26.2%	Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022	Jun 30, 2022	96	+4.3%	Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022	Mar 31, 2022	85	+7.6%	Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021	Dec 31, 2021	92	-1.1%	Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021	Sep 30, 2021	84	-6.7%	Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021	Jun 30, 2021	92	+16.5%	Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021	Mar 31, 2021	79	-1.2%	Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020	Dec 31, 2020	93	+16.3%	Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020	Sep 30, 2020	90	+13.9%	Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020	Jun 30, 2020	79	0.0%	Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020	Mar 31, 2020	80	+2.6%	Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗
Q4 2019	Dec 31, 2019	80	+8.1%	Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
Q3 2019	Sep 30, 2019	79	+11.3%	Form 8-K (amgn-2019930xq3exhibit.htm, filed 2019-10-29) ↗
Q2 2019	Jun 30, 2019	79	–	Form 8-K (amgn-2019630xq2exhibit991f.htm, filed 2019-07-30) ↗
Q1 2019	Mar 31, 2019	78	–	Form 8-K (amgn-2019331xq1exhibit991f.htm, filed 2019-04-30) ↗
Q4 2018	Dec 31, 2018	74	–	Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗
Q3 2018	Sep 30, 2018	71	–	Form 8-K (exhibit991financialresults.htm, filed 2018-10-30) ↗

Cite this data

StockData. (2026). Amgen Vectibix (panitumumab — Metastatic Colorectal Cancer) — U.S. product sales ($M) ($M), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_vectibix_us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.